Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024 15:20 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease,...
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
January 24, 2024 08:35 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
January 04, 2024 09:34 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined...
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
December 18, 2023 09:39 ET
|
Immix Biopharma, Inc.
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized...
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
December 11, 2023 09:36 ET
|
Immix Biopharma, Inc.
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6...
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
November 30, 2023 09:46 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
November 22, 2023 09:19 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies...
Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht
November 22, 2023 03:20 ET
|
Immix Biopharma, Inc.
NEXICART-2 weitet Studien mit NXC-201 bei rezidivierter/refraktärer AL-Amyloidose nach IND-Freigabe auf Prüfzentren in den USA aus 72 Patienten außerhalb der USA, die zuvor mit NXC-201 behandelt...
La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains
November 22, 2023 03:20 ET
|
Immix Biopharma, Inc.
À la suite de l’autorisation de la FDA, NEXICART-2 va poursuivre les essais sur le NXC-201 dans le traitement de l’amylose AL en rechute ou réfractaire sur les sites américains 72 patients ont déjà...
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023 09:46 ET
|
Immix Biopharma, Inc.
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain...